Secondary prevention trials for coronary artery disease with antibiotic treatment for Chlamydia pneumoniae: design issues

scientific article

Secondary prevention trials for coronary artery disease with antibiotic treatment for Chlamydia pneumoniae: design issues is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P356DOI10.1016/S0002-8703(99)70298-X
P698PubMed publication ID10539871

P2093author name stringKronmal RA
Grayston JT
Jackson LA
Kennedy WJ
P2860cites workPrevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsQ29620696
Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits.Q35559048
Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with ChlamydQ37878769
High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors.Q37880679
Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit modelQ37881464
Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study GroupQ37882250
Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarctionQ37882420
P433issue5 Pt 2
P407language of work or nameEnglishQ1860
P921main subjectcoronary artery diseaseQ844935
Chlamydia pneumoniaeQ62869737
P304page(s)S545-9
P577publication date1999-11-01
P1433published inAmerican Heart JournalQ2227156
P1476titleSecondary prevention trials for coronary artery disease with antibiotic treatment for Chlamydia pneumoniae: design issues
P478volume138